Grail, Inc. (NASDAQ:GRAL - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $17.14, but opened at $16.56. Grail shares last traded at $16.83, with a volume of 23,521 shares changing hands.
Analyst Upgrades and Downgrades
A number of research firms have commented on GRAL. Guggenheim initiated coverage on shares of Grail in a research report on Thursday, October 17th. They set a "neutral" rating on the stock. Morgan Stanley began coverage on Grail in a research report on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 target price for the company. Finally, Wolfe Research assumed coverage on Grail in a research report on Friday, November 15th. They set a "peer perform" rating on the stock.
View Our Latest Report on Grail
Grail Stock Performance
The stock's fifty day moving average price is $16.46.
Insider Buying and Selling
In related news, CEO Robert P. Ragusa sold 123,454 shares of Grail stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total value of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares of the company's stock, valued at approximately $8,589,507.22. This trade represents a 16.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Aaron Freidin sold 30,452 shares of the company's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the sale, the chief financial officer now directly owns 268,277 shares of the company's stock, valued at $3,761,243.54. This represents a 10.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have acquired 58,829 shares of company stock worth $757,298 in the last ninety days.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Further Reading
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
